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Physiology of the glycocalyx 
 
The endothelial glycocalyx (EG) is a carbohydrate-rich scaffold of proteoglycans and 
glycosaminoglycans on the luminal surface of endothelial cells.1 The main proteoglycans are the 
syndecans (Figure 1). These structures are transmembrane and play a role in transmitting shear stress 
signals to the cytoskeleton of the endothelial cell and also changing their binding capacity according to 
intracellular signalling pathway activation. They also provide an anchor for glycocoaminoglycans such 
as heparan sulfate. Another important glycosaminoglycan is hyaluronan, which weaves its way through 
the glycocalyx and is anchored by cell surface receptors such as CD44.  
 
Figure 1 – The main components of the endothelial glycocalyx 
 
The meshwork of carbohydrates and 
proteins creates an immobile plasma layer 
and barrier, preventing interaction between 
cells in circulation and endothelial cells. It 
does this by physically ‘hiding’ 
glycoproteins such as selectins, integrins and 
immunoglobulins.2 This prevents adhesion 
of platelets and white blood cells. It also 
discourages thrombosis by housing 
anticoagulants such as antithrombin III and 
tissue factor pathway inhibitor. 
 
The EG also plays a role in the endothelial 
response to shear stress. Increased flow 
leads to local nitric oxide production, with 
subsequent vasodilation, and increased 
vascular permeability, both mediated via the 
EG.3 The EG can also change in thickness under certain flow rates. Evidence suggests that the EG 
becomes thicker under low flow rates, increasing vascular resistance, likely due to adherence of plasma 
components.4 Under high flow rates, the actual thickness of the EG appears unaffected if the blood is 
diluted with plasma.5 However, saline haemodilution decreases vascular resistance independent of a 
reduction in blood viscosity and shear-induced vasodilation. This effect is likely due to loss of the EG 
and an increase in intra-luminal diameter due to ‘washout’ of soluble glycocalyx constituents. 
 
The EG plays an important role in fluid flux across the endothelium, which has led to a revision of the 
traditional Starling’s forces.6 Albumin molecules within the EG layer provides some oncotic pressure, 
and it is the oncotic balance between the intravascular (flowing) compartment and the EG compartment 
that affects fluid flux according to protein levels. This explains why raising oncotic pressure in the 
intravascular compartment does not actually draw fluid from the interstitial space, much to the 
disappointment of clinicians attempting to reduce peripheral oedema. However, delivering a fluid with 
iso-oncotic or hyper-oncotic properties serves to hold fluid in the intravascular compartment and 
diminish fluid flux through the EG layer. Therefore, this strategy of fluid therapy may still serve a 
purpose in critical care to maintain effective circulating blood volume while allowing restriction of 
crystalloid fluids in the oedematous patient. When choosing any combination of fluid types, it must 
always be tailored to the individual patient with recognition that no one strategy has been shown to be 
broadly effective over another.  
 
Shedding of the glycocalyx due to injury 
 
Pro-inflammatory mediators, such as tissue necrosis factor-α (TNFα), interleukin-1β, 









shedding of the EG.7-18 Endocan has also been shown to be shed from endothelial cells by LPS.16 
Syndecan-4 is also shed by TNFα from the glomerular endothelial cells.11 Thrombin and plasmin have 
both been shown to cleave syndecan-1 and -4 in cell culture.12-14 It is likely that shedding of the EG is 
one of the first steps in inflammation and coagulation, which then allows interactions between 
endothelial cells and circulating leucocytes and platelets.4,19-22 The timing of this process, whether the 
EG sheds first or activated leucocytes promote EG shedding, has not been fully explored in a clinical 
model and may differ between circumstances. Loss of the glycocalyx will also have effects on 
mechanotransduction however the exact process is still being characterised.23 
 
Many in vivo experimental studies have demonstrated EG shedding in response to a variety of stimuli, 
including inflammatory mediators,15,17 endotoxin,18 and crystalloid fluid therapy.24 In one study that 
mimicked a clinical scenario, a porcine trauma model, syndecan-1 increased within 15 minutes of 
injury.25 Clinical research assessing glycocalyx biomarkers in critically ill people is limited to fairly 
small studies. Syndecan-1 has been shown to be higher in septic ICU populations, compared to healthy 
controls,26,27 post-abdominal surgery patients28 and healthy men injected with LPS.29 Syndecan-1 is 
also increased in trauma patients on admission to ED.30-32 Endocan has been shown to be higher than 
healthy controls in patients with sepsis, according to severity,16,33 and in trauma patients.34 Heparan 
sulfate has also been shown to be increased in sepsis35-37 with one study showing that levels were 
higher in non-survivors.37 Interesting, in one study using healthy men, it took 24 hours for heparan 
sulfate levels to significantly increase after injection of TNFα.18 Hyaluronan has been shown to be 
increased in one small septic population38 and in ICU patients receiving mechanical ventilation,36 
whereby higher levels were found in patients with a pulmonary source of sepsis compared to an extra-
pulmonary source. People with out-of-hospital cardiac arrest had increased hyaluronan 48-72 hours 
after the event, but not in the first 6 hours, therefore, similar to heparan sulfate, this marker may also be 
slow to rise after the initial insult.39  
 
Common to the clinical studies previously mentioned is a limitation of cohorts to ICU patients; post-
intervention and late in the disease process. Blood volume expansion is a key first-line intervention in 
many types of critical illnesses and fluid boluses have been shown to increase EG damage markers.24,40 
Combined with the insult of inflammation, large-bolus fluid therapy may further enhance EG damage, 
and heavily influence the degree of marker increase in ICU populations.   
 
Shedding of the glycocalyx due to intravenous fluid therapy 
 
There is some evidence that rapid intravenous crystalloid fluid therapy, without coinciding injury or 
inflammation, can increase EG damage markers.24,40 In one study, healthy euvolaemic men were 
bolused one of three fluid types; 7.1ml/kg of dextrans or albumin, or 21.4ml/kg of Ringer’s acetate.24 
The Ringer’s acetate group had an increase in an EG damage biomarkers, whereas the other two fluid 
types did not. Interestingly, the dextrans group showed the lowest levels 3 hours after the infusion. It is 
unknown if this response to blood volume expansion is related shear stress, release of atrial natriuretic 
peptide,41,42 dilution of EG constituents, or a combination of these factors. In studies using euvolaemic 
models, it is difficult to separate the effects of hypervolaemia from the effects of the fluid infusion 
itself and the scenario is less applicable to emergency medicine. One controlled-haemorrhage shock 
model using mice compared fluid resuscitation with either Lactated Ringer’s (three x shed volume) or 
fresh frozen plasma (FFP)(one x shed volume).43 The group that received FFP had less lung 
hyperpermeability, less lung myeloperoxidase content, and less EG shedding. However, it is unknown 
if this effect was due to the provision of plasma constituents or the lower volume used for resuscitation.  
 
Evidence of glycocalyx damage in the dog 
 
Unfortunately, there is little information on the presence of glycocalyx damage in the dog. Research is 
limited by poor availability of quality assays to measure biomarkers of EG damage. One paper 
describing a sepsis model in dogs used assays that were not validated for the dog therefore results are 
questionable.44 Our group has had success with measuring hyaluronan via ELISA in dogs in shock, but 
assays for syndecan-1 have been disappointing thus far. Sidestream darkfield microscopy shows some 
promise in estimating the thickness of the glycocalyx via imaging capillaries in the buccal mucosa. 
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